drugset / Trial / NCT00834418

Leflunomide 20 mg Tablets Under Fasting Conditions

NCT00834418

Phase 1 Completed 84 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupOpen-labelOther

Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 20 mg Leflunomide Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 20 mg ARAVA™ Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 20 mg tablet) in healthy adult subjects under fasting conditions.

Timeline

Start
2002-06
Primary completion
2002-07
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule 20 mg Oral

Indications

No indication recorded.